Article Figures & Data
Tables
PsA With Axial Involvement, n = 24 PsA Without Axial Involvement, n = 49 P OR (95% CI) Male, n (%) 10 (42) 21 (43) 0.9 0.9 (0.3–2.5) Age, yrs, mean (SD) 49 (9.6) 51 (13.6) 0.5 Smoker, n (%) 17 (71) 26 (54) 0.1 2.1 (0.7–6.6) Peripheral arthritis, n (%) 24 (100) 47 (97) 0.9 Clinical enthesopathy, n (%) 11 (45) 11 (22) 0.6 0.5 (0.4–6.3) PsO, n (%) 19 (79) 37 (75) 0.7 1.2 (0.4–4) Others SpA features: IBD-uveitis, n (%) 10 (42) 6 (12) 0.004 5.1 (1.5–17) Family history of SpA, n (%) 6 (25) 18 (36) 0.3 0.6 (0.2–1.7) VAS pain (0–10), median (IQR) 7 (5–8) 6 (3–7) 0.1 TJC28, median (IQR) 4 (1–4.7) 2 (0–4) 0.1 SJC28, median (IQR) 2 (0–3) 1 (0–2.5) 0.8 DAPSA, mean (SD) 15 (4.6) 13 (8.5) 0.3 MASES, median (IQR) 0.5 (0–2) 0 (0–1) 0.04 HAQ-DI, median (IQR) 0.8 (0.5–1) 0.5 (0.1–0.8) 0.002 CRP, median (IQR) 2 (1–10) 2 (1–6) 0.8 CRP+ (> 5 mg/L), n (%) 9 (39) 18 (36) 0.8 1.1 (0.4–3) ESR, mm/h, median (IQR) 19 (10–25) 16 (7.5–26) 0.3 Positive peripheral radiograph, n (%) 14 (59) 20 (41) 0.2 2 (0.6–6.5) Enthesopathy by US, n (%) 10 (43) 23 (48) 0.7 0.8 (0.3–2.2) Synovitis by US, n (%) 11 (46) 22 (45) 0.9 1 (0.4–2.8) Time between the onset of the symptoms and access to the program, months, median (IQR) 60 (18–122) 36 (8–78) 0.1 Values in bold are statistically significant. CRP: C-reactive protein; DAPSA: Disease Activity for Psoriatic Arthritis; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire-Disability Index; IBD: inflammatory bowel disease; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; PsA: psoriatic arthritis; PsO: psoriasis; SJC28: swollen joint count in 28 joints; SpA: spondyloarthritis; TJC: tender joint count in 28 joints; US: ultrasonography; VAS: visual analog scale.
AxPsA, n = 24 AxSpA, n = 64 P OR 95% CI Male sex, n (%) 10 (42) 29 (45) 0.8 0.9 0.3–2.2 Age at diagnosis, yrs, mean (SD) 49.4 (9.6) 43.8 (12.7) 0.03 Smoking, n (%) 51 (71) 22 (34) 0.003 4.7 1.6–14 Peripheral arthritis, n (%) 21 (87) 13 (20) > 0.001 27.6 7–106 Enthesitis, n (%) 11 (46) 21 (33) 0.25 1.7 0.6–4.5 PsO, n (%) 19 (79) 0 (0) > 0.001 IBD and/or uveitis, n (%) 10 (42) 9 (14) 0.005 4.3 1.5–13 Family history of SpA, n (%) 6 (25) 20 (31) 0.5 0.7 0.2–2.1 Positive peripheral radiograph, n (%) 10 (59) 1 (2) > 0.001 61.4 7–557 Positive enthesis US, n (%) 10 (42) 23 (43) 0.9 1.0 0.4–2.9 Positive joints US, n (%) 10 (45) 6 (12.5) 0.002 5.8 1.7–19 Inflammatory low back pain, n (%) 21 (91) 56 (87) 0.6 1.5 0.3–7.6 Good response to NSAID, n (%) 22 (82) 43 (70) 0.3 1.8 0.5–6.3 Positive sacroiliac test, n (%) 17 (74) 33 (52) 0.07 2.5 0.9–7.3 Morning stiffness, min, median (IQR) 40 (30–45) 30 (15–40) 0.04 VAS pain (0–10), median (IQR) 7 (5–7) 7 (6–8) 0.03 VAS night pain (0–10), median (IQR) 7 (5–7) 6 (4–7.5) 0.8 BASDAI, mean (SD) 4 (1.7) 4.5 (1.6) 0.2 BASFI, median (IQR) 4.6 (3.8–5.3) 4.6 (4–6) 0.6 MASES, median (IQR) 0.5 (0–2) 0 (0–1) 0.2 HAQ-DI, median (IQR) 0.8 (0.5–1) 0.75 (0.5–1) 0.2 Positive HLA-B27, n (%) 4 (17) 30 (49) 0.006 0.2 0.06–0.7 CRP, median (IQR) 2 (1–10) 2 (1–6) 0.6 ESR, median (IQR) 19 (10–25) 17 (10–25) 0.6 Positive sacroiliac MRI, n (%) 9 (37) 44 (72) 0.003 0.2 0.85–0.6 Positive sacroiliac radiograph, n (%) 7 (32) 30 (52) 0.1 0.4 0.14–1.1 Time from onset of low back pain to evaluation, months, median (IQR) 60 (18–122) 40 (17–122) 0.9 Values in bold are statistically significant. AxPsA: axial psoriatic arthritis; AxSpA: axial spondyloarthritis; CRP: C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire-Disability Index; IBD: inflammatory bowel disease; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; MRI: magnetic resonance imaging; NSAID: nonsteroidal antiinflammatory drug; PsA: psoriatic arthritis; PsO: psoriasis; SpA: spondyloarthritis; US: ultrasonography; VAS: visual analog scale.
Additional Files
2001627 Video Abstract
